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Abstract
Microvillus inclusion disease (MVID) is a rare but fatal autosomal recessive congenital diar-
rheal disorder caused by MYO5B mutations. In 2013, we launched an open-access registry
for MVID patients and their MYO5B mutations (www.mvid-central.org). Since then, additional
uniqueMYO5Bmutations have been identified in MVID patients, but also in non-MVID patients.
Animal models have been generated that formally prove the causality between MYO5B and
MVID. Importantly, mutations in two other genes, STXBP2 and STX3, have since been associated
with variants of MVID, shedding new light on the pathogenesis of this congenital diarrheal
disorder. Here, we review these additional genes and their mutations. Furthermore, we discuss
recent data from cell studies that indicate that the three genes are functionally linked and,
therefore, may constitute a common disease mechanism that unifies a subset of phenotypically
linked congenital diarrheal disorders. We present new data based on patient material to sup-
port this. To congregate existing and future information on MVID geno-/phenotypes, we have
updated and expanded the MVID registry to include all currently known MVID-associated gene
mutations, their demonstrated or predicted functional consequences, and associated clinical
information.
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1 MICROVILLUS INCLUSION DISEASE: AN
EXPANDING SPECTRUM OF GENES AND
PHENOTYPES
In 1978, Davidson and coworkers reported five infants that presented
with an apparent congenital enteropathy characterized by persistent
diarrhea from birth, the inability to absorb nutrients, failure to thrive,
and leading to death (Davidson, Cutz, Hamilton, & Gall, 1978). At the
cellular level, atrophy of the apical brush border membrane of the
enterocytes, intracellular accumulation of brush border enzymes,
and occasional microvilli-lined inclusion bodies named microvillus
inclusions were identified as characteristic features for this disease
(Cutz et al., 1989; Davidson et al., 1978). This congenital enteropathy
has been called Davidson Disease, intractable diarrhea of infancy,
congenital familial protracted diarrhea with enterocyte brush bor-
der defects, congenital microvillus atrophy, or microvillus inclusion
disease (MVID) (Cutz et al., 1989), and is listed in Online Mendelian
Inheritance in Man (OMIM) as Diarrhea 2, with microvillus atrophy
(DIAR2; #251850). To date, MVID is the most frequently used name
for this disease in the scientific literature (source:Web of science).
The diagnosis of MVID is based on microscopical biopsy evalu-
ation, and includes the detection of Periodic acid-Shiff (PAS) stain-
ing in the apical cytoplasm, immunohistochemical detection of the
brush border metallopeptidase CD10 in the apical cytoplasm, and the
detection of microvillus inclusions in the enterocytes with electron
microscopy. A focal appearance of MVID-typical enterocyte defects
has been reported, which seems associated with a late-onset or milder
clinical course of the disease (Perry et al., 2014). Notably, phenotypic
variations have been reported in patients with clinical presentations
that are entirely typical forMVID. These include for examplemicrovilli
at the lateral surface ofMVID enterocytes (Croft et al., 2000;Morroni,
Cangiotti, Guarino, &Cinti, 2006; Phillips& Schmitz, 1992;Wiegerinck
et al., 2014) or aggregates of electron-lucent membranous vesicles
(Weeks, Zuppan, Malott, & Mierau, 2003). In some cases, microvillus
inclusions could not be detected (Iancu, Mahajnah, Manov, & Shaoul,
2007; Mierau, Wills, Wyatt-Ashmead, Hoffenberg, & Cutz, 2001) or
only small ones could be detected after several attempts (Weeks et al.,
2003). These phenotypic variations have led to suggest thatMVID rep-
resents aheterogeneousdisease (Iancuet al., 2007;Mierauet al., 2001;
Weeks et al., 2003).
In 2008, mutations in the MYO5B gene (chromosome 18q21.1;
MIM# 606540) were identified in MVID patients (Erickson, Larson-
Thomé, Valenzuela, Whitaker, & Shub, 2008; Müller et al., 2008), and
confirmed MVID as an autosomal recessive disease. MYO5B encodes
the myosin Vb protein, which belongs to the large myosin family
of actin-based molecular motor proteins and controls intracellular
trafficking. RNAi-mediated knockdown of myosin Vb in an intestinal
cell line reproduced several of the disease phenotypes, supporting
the causality between MYO5B and MVID (Ruemmele et al., 2010).
Between 2008 and 2013, a total of 41 uniqueMYO5Bmutations were
identified, which were systematically analyzed, categorized, and col-
lected in an online registry for MVID patients (van der Velde et al.,
2013) (www.mvid-central.org). Since then, more unique homozygous
and compound heterozygous MYO5B mutations have been identi-
fied in MVID patients. Furthermore, animal models for MVID have
been developed, formally proving the connection betweenMYO5B and
MVID. Notably, in some MVID patients, noMYO5Bmutations, or only
one heterozygousMYO5Bmutation was detected (Müller et al., 2008;
Perry et al., 2014; Szperl et al., 2011), and the possibility that other
genes are involved was suggested.
Recently, mutations in two other genes have been associated with
variant forms of MVID: STX3 (chromosome 11q12.1; MIM# 600876)
(Wiegerinck et al., 2014) and STXBP2 (chromosome 19p13.2; MIM#
601717) (Stepensky et al., 2013; Vogel et al., 2017). STX3 encodes
the syntaxin-3 protein, which is a member of the Qa-SNARE protein
family that contributes a glutamine (Q) residue for the formation of
the assembled core SNARE complex. STXBP2 encodes the syntaxin-
binding protein-2 also called the mammalian uncoupled munc18-2
protein, which belongs to the sec1/munc18-like protein family. Both
syntaxin-3 and munc18-2 play a role in membrane fusion. STX3muta-
tions were identified by whole exome sequencing in two patients diag-
nosed with MVID based on clinical symptoms but without MYO5B
mutations (Wiegerinck et al., 2014). Immunohistochemical analyses
of intestinal biopsies revealed intra-cytoplasmic PAS staining, vari-
able microvillus atrophy, microvillus inclusions and, unlike “classical”
MVID, the appearance of microvilli at the basolateral plasma mem-
brane (Wiegerinck et al., 2014). STXBP2 mutations were identified
in patients with familial hemophagocytic lymphohistiocytosis type 5
(FHL5, OMIM 613101). Although FHL5 is primarily regarded as a
hyper-inflammatory immune disorder, ∼40% of FHL5 patients show
severe chronic diarrhea starting shortly after birth without signs of
infection and often preceding the diagnosis of FHL5. Most of these
patients require long-term total parenteral nutrition (TPN) for sur-
vival. Therapies targeted against FHL5 failed to resolve the diarrhea
which persisted even after full hematopoietic stem cell transplanta-
tion (Pagel et al., 2012), indicating that the intestinal symptoms are
independent of immune cell defects. Immunohistochemical analyses of
intestinal biopsiesof thesepatients revealed the intracellular retention
of apical brush border proteins such as CD10 and PAS-positive mate-
rial, variable microvillus atrophy and microvillus inclusions (Stepensky
et al., 2013; Vogel et al., 2017). Thus, these patients show all intestine-
related clinical and cellular hallmarks of MVID (Stepensky et al., 2013;
Vogel et al., 2017).
2 MVID-ASSOCIATED GENES ARE
FUNCTIONALLY LINKED
The striking overlap in intestinal symptoms and cellular phenotypes
between patients carrying eitherMYO5B, STX3, or STXBP2 mutations
and the previously reported roles of their encoded proteins in api-
cal membrane trafficking in epithelial cells led to suggest that these
three genes and their encoded proteins represent a common dis-
ease mechanism that unifies a subset of phenotypically linked con-
genital diarrheal disorders (Posovszky, 2016; Stepensky et al., 2013;
Vogel et al., 2017; Wiegerinck et al., 2014).MYO5B, STX3, and STXBP2
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regulate protein trafficking to the apical brush border. Myosin Vb is
an actin-based molecular motor protein that controls the trafficking
of endosomes/transport vesicles to the apical brush border. Syntaxin-
3 and munc18-2 are part of a protein complex that controls the
membrane fusion of transport vesicles with the apical brush border.
Indeed, the trafficking of proteins to the apical brush border mem-
brane of intestinal epithelial Caco-2 cells is inhibited upon loss-of-
function of either myosin Vb (Knowles et al., 2014; Kravtsov et al.,
2014, 2016; Ruemmele et al., 2010; Vogel et al., 2015), syntaxin-
3 (Breuza, Fransen, & Le Bivic, 2000; Collaco, Marathe, Kohnke,
Kravstov, &Ameen, 2010; Riento, Kauppi, Keranen, &Olkkonen, 2000;
Vogel et al., 2015;Wiegerinck et al., 2014), or munc18-2 (Riento et al.,
2000; Vogel et al., 2015, 2017). Also, apical microvillus atrophy was
observed in Caco-2 cells upon loss-of-function of either myosin Vb
(Dhekne et al., 2014; Knowles et al., 2014; Ruemmele et al., 2010;
Vogel et al., 2015) or syntaxin-3 (Vogel et al., 2015; Wiegerinck et al.,
2014). Further, loss of myosin Vb function in enterocytes of MVID
patients with MYO5B mutations (Dhekne et al., 2014; Szperl et al.,
2011) and in enterocytes of Myo5B knockout mice (Weis et al., 2016)
resulted in themislocalizationof themyosinVb-bindingprotein rab11a
(Szperl et al., 2011), and the loss of either myosin Vb or rab11a in
murine enterocytes caused the mislocalization of syntaxin-3 (Knowles
et al., 2015; Weis et al., 2016). Moreover, myosin Vb—when bound to
rab11a—was found to interact with syntaxin-3 in intestinal epithelial
cells, and the knockdown ofmyosin Vb protein expression resulted in a
strongly reduced interactionbetween syntaxin-3andmunc18-2 (Vogel
et al., 2015).
To provide further support thatmyosin Vb, syntaxin-3 andmunc18-
2 are also linked in patient tissue, we have analyzed the subcellular dis-
tribution of syntaxin-3 andmunc18-2 in enterocytes of intestinal biop-
sies from patients with MYO5B or STXBP2 mutations. We found that
munc18-2 and syntaxin-3 (and two additional members of the apical
membrane fusion machinery, SNAP23 and cellubrevin; Galli, Brenna,
Camilli de, & Meldolesi, 1976; Low et al., 1998; Riento et al., 2000))
all localized to the apical brush border plasma membrane in control
enterocytes, but accumulated in intracellular puncta in the entero-
cytes of two MVID patients (Szperl et al., 2011), one with a homozy-
gous c.4366C > T (p.Gln1456*) MYO5B mutation (Figure 1A–D) and
one with compound heterozygous c.1540T > C (p.Cys514Arg) and
IVS33+3753G > T MYO5B mutations (Supp. Figure S1A). Further-
more, in a biopsy of an FLH5 patient with a variant MVID phenotype
and a homozygous c.693_695delGAT (p.Ile232del)mutation in STXBP2
(Stepensky et al., 2013), we found that syntaxin-3 was mislocalized
from the enterocyte brush border membrane to intracellular puncta
(Figure 1E). This is in agreement with a previous study that demon-
strated a function for munc18-2 in the subcellular distribution of
syntaxin-3 in a different cell type (Hackmann et al., 2013). Investiga-
tion of the subcellular distribution of myosin Vb was precluded by the
lack of good quality antibodies for use on paraffin-embeddedmaterial.
Together, the published in vitro data and the patient-based data
as shown in this study provide compelling evidence that myosin Vb,
syntaxin-3, and munc18-2 are functionally linked in human entero-
cytes, and likely comprise a common molecular pathway and disease
mechanism that unifies a subgroup of congenital diarrheal disorders
centered around MVID (Overeem, Bryant, & van IJzendoorn, 2015;
Posovszky, 2016; Vogel et al., 2017).
Although most of the cell line-based studies involve the general
knockdown of myosin Vb, syntaxin-3, or munc18-2, patients typically
carry one or more of specific MYO5B, STX3, or STXBP2 mutations
(van der Velde et al., 2013). These mutations are likely to result in
the expression of mutated proteins, however direct experimental
evidence of the mutations functional consequence is missing. Such
data are eagerly awaited in order to understand and describe how
the phenotype, impact, or onset of the disease might differ depending
on the mutations. This is further emphasized by the fact thatMYO5B,
STX3, and STXBP2 mutations have also been identified in patients
without intestinal symptoms (Chograni et al., 2015; Gonzales et al.,
2017; Pagel et al., 2012; Qiu et al., 2017) (see below). Therefore, it is
important to understand how the differentMYO5B, STX3, and STXBP2
mutations and the affected residues may impact the function of the
encoded proteins.
3 MYO5B GENE MUTATIONS
In 2013, we reviewed and categorized 41 reported MVID-associated
MYO5Bmutations (van der Velde et al., 2013). Here we have retrieved
from the literature all additional MVID patients reported between
2013 and 2017. Throughout this article, we have used the DNA and
protein variant numbering system following the guidelines of the jour-
nal and Human Genome Variation Society (HGVS). Twenty of these
additional patients were demonstrated to carry one or more MYO5B
mutations, expanding the number of unique MVID-associatedMYO5B
mutations to 62 (Figure 2A and B and Supp. Table S1A). Myosin Vb
generates force via its motor domain upon conformational rearrange-
ments driven by F-actin binding coordinated with ATP hydrolysis. The
motor domain is composed of four main subdomains: the N-terminal,
upper 50 kDa (U50), lower 50 kDa (L50) subdomains, and the con-
verter (Figure 2A and C). The myosin V elongated lever arm (which
contains the converter and the 6 IQ-motifs bound to 6 light chains),
swings and produces large displacements by amplifying small move-
mentswithin the catalyticmotor domain during the chemo-mechanical
acto-myosin cycle (Houdusse & Sweeney, 2016). Finally, the myosin
V C-terminal tail binds several partners/cargoes and is composed of
a long coiled-coil region allowing motor dimerization and a terminal
globular tail domain (Trybus, 2008) . The localization of the consequen-
tial amino acid substitutions in a homology model of the 3D structure
of the myosin Vb motor domain (Figure 2C) is depicted in Figure 2D.
ForMYO5Bmutation analyses, reference sequence NM_001080467.2
was used.
Of the 25 MYO5B mutations found in these additional patients,
four compound heterozygousMYO5Bmutations and one homozygous
MYO5B mutation present in five patients of different families were
previously reported in other MVID patients of unrelated families
(this study). These patients were indeed found to carry either a het-
erozygous (c.3163-3165dupCTC (p.Leu1055dup) and c.445C > T
(p.Gln149*)), compound heterozygous (c.3163-3165dupCTC
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F IGURE 1 The apical SNAREmachinery in duodenal enterocytes of patients withMYO5B or STXBP2mutations.A: Labeling ofmunc18-2 (green)
and nuclei (blue) in control (1) andMVID (2) enterocytes.B: Labeling of syntaxin-3 (green) and nuclei (blue) in control (1) andMVID (2) enterocytes.
C: Labeling of SNAP23 (green) andDNA (blue) in control (1) andMVID (2) enterocytes.D: Labeling of cellubrevin (green) andDNA (blue) in control
(1) andMVID (2) enterocytes. E: Labeling of syntaxin-3 (green) and DNA (blue) in control (1) and FHL5 (2) enterocytes. Asterisks indicate position
of the lumen. Arrows in A2, B2, and C2 point to globular structures in the apical cytoplasm
(p.Leu1055dup)), or homozygous (c.656G > A (p.Arg219His),
c.5383A > T (p.1795Leu) and c.1323-2A > G (IVS10-2A > G))
mutations (van der Velde et al., 2013). The homozygous patient
with the c.656G > A (p.Arg219His) mutation displayed early onset
MVID, whereas the patient who was compound heterozygous for
this mutation displayed late-onset MVID. Furthermore, heterozygous
c.656G > A (p.Arg219His) mutations have been associated with colon
carcinoma in the COSMIC database (cancer.sanger.ac.uk). The com-
pound heterozygous c.3163-3165dupCTC mutation (p.Leu1055dup)
currently has been reported in three unrelated families of different
ethnic origin, also including patients with early-onset and patients
with late-onset MVID. The c.3163-3165dupCTC (p.Leu1055dup)
mutation (rs10625857)) is not likely to be pathogenic as such as it has
been reported at least 41,262 times of which 7,704 in a homozygous
manner, and has the highest reported allele frequency (0.3420) in the
ExAC database (exac.broadinstitute.org). One heterozygous patient
carrying this c.3163-3165dupCTC (p.Leu1055dup) mutation and a
c.1347delC (p.Phe450leufs*30) mutation displayed late onset MVID
and could be weaned of TPN and moved to normal enteral feeding
(Perry et al., 2014). Given the autosomal recessive inheritance pattern
of MVID, this suggests that the c.3163-3165dupCTC (p.Leu1055dup)
mutationmay contribute to the onset of clinical symptoms.
The 21 new MVID-associated MYO5B mutations include seven
nonsense, eight missense, and five splicing mutations and one small
deletion. These mutations are found in both the N-terminal motor
domain and in theC-terminal tail domain of themyosinVbprotein (Fig-
ure 2A and B). We have examined these mutations in the light of cur-
rent understanding of howmyosinmotors produce force, as previously
reviewed (Houdusse & Sweeney, 2016) as well as based on the cur-
rent structural data available for the myosin V tail (Nascimento et al.,
2013; Pylypenko et al., 2013; Velvarska & Niessing, 2013). The results
of these examinations are summarized in Supp. Table S1A. Interest-
ingly, the three newly reported amino acid substitutions in the motor
domain p.Leu528Phe, p.Phe538Ser, p.Ile550Phe, resulting from the
c.1582C> T, c.1316T>C, and c. 1648A> TMYO5Bmutations, respec-
tively, affect residues that interact with each other, forming a buried
hydrophobic core of the lower part of the L50 subdomain (seemodel in
Figure2CandD).All three substitutionswill havedestabilizing effect in
the folding of this region of the L50 subdomain. Themutant side chains
are also close to the activation loop and loop3 that are both involved
in actin binding; thus, these mutations likely affect filamentous actin-
binding and motility properties. Specifically, Phe538 is a part of loop-
3 that is involved in F-actin binding; the bulky hydrophobic side chain
determines the relative orientation of the helix-loop-helix and loop-
3. The Phe538 substitution to the small polar serine side chain will
impact the conformational stability of the actin-binding elements and
will thus likely affect the force produced by themotor on actin. Leu528
belongs to the second helix of the helix-loop-helix motif that plays an
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F IGURE 2 Schematic representation of the myosin Vb protein. A: A schematic overview of the myosin Vb protein and its functional domains.
Protein data are deduced from Genbank RefSeq-file accession number NG_012925.1 for the humanMYO5B gene. Nucleotide numbering reflects
cDNAnumberingwith+1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to the journal guide-
lines (www.hgvs.org/mutnomen). The initiation codon is 1. B: Overviews of the MVID-associated MYO5B mutations in the different domains of
the myosin Vb protein. IQ1-6 refers to the six calmodulin-binding IQ domains that conform to the consensus sequence [I,L,V]QxxxRGxxx[R,K].
Mutations indicated in black, red, blue, and gray letter color representmissense, frameshift/nonsense, deletions/insertions, and splicingmutations,
respectively. The differently colored blocks associated with each mutation in the protein domains represent the predicted consequences for the
protein (black: premature termination,magenta:mutations in regions important for the allosteric rearrangements of themyosinmotor head during
the kinetic cycle, orange:mutations thatmay lead to proteinmisfolding, red:mutations in the ATP-binding site, green:mutations in regions that are
important for actin interactions). Black lines between individual mutations indicate their combined presence in a single patient. C: Model of the
myosin Vb motor domain. A. Homology model of myosin Vb based on myosin Va post-rigor structure with ATP nucleotide bound (PDB ID: 1W7J)
is shown. Themotor domain contains four subdomains (the N-terminal: gray, including the SH3: light gray, the U50: marine blue, the L50: sand, and
the converter: green). Conformational changes in the motor domain are amplified by the lever arm (converter, green; IQ motif 1, pale cyan helix
associated with a calmodulin (light pink); the 5 other IQ motifs of the lever arm are not shown). These conformational changes are coordinated
within the motor by elements of the transducer (loop 1: light purple, central beta sheet: cyan) as well as the connectors (Relay: yellow, SH1 helix:
red, Strut: hot pink), which are linkers between subdomains. The nucleotide-binding elements (P-loop: pale green, Switch I: magenta, and switch
II: orange) surrounding the nucleotide (represented in black sticks) and the actin-binding elements (helix-loop-helix: brown, HCM loop: wheat) are
also depicted. D: The MVID-associated missense mutations found in the motor domain of myosin Vb are depicted with the following color code:
(green: mutations in regions that are important for actin interactions, red: mutations in the ATP-binding site, Magenta: mutations in regions of
importance for allosteric rearrangements of themyosin head during themotor cycle, orange: mutations that may lead to protein misfolding)
essential role in F-actin binding,while Ile550 is locatedon abeta strand
preceding loop-3. Both aliphatic side chains are tightly packed in the
L50 subdomain hydrophobic core and their substitution to a bulky
phenylalanine aromatic side chain may change the relative orientation
of the secondary structure elements of this actin-binding unit. In con-
clusion, these substitutions can be classified as both affecting the sta-
bility of the L50 fold and actin-binding properties of myosin Vb and
thus the force produced by this myosin motor.
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F IGURE 3 AandB: Overview of the non-MVID/intrahepatic cholestasis-associatedMYO5Bmutations in the different domains of themyosin Vb
protein. Mutations indicated in black, red, blue, and gray letter color represent missense, frameshift/nonsense, deletions/insertions, and splicing
mutations, respectively. Thedifferently coloredblocks associatedwitheachmutation in theproteindomains represent thepredicted consequences
for the protein (black: premature termination,magenta:mutations in regions important for the allosteric rearrangements of themyosinmotor head
during the kinetic cycle, orange: mutations that may lead to protein misfolding, red: mutations in the ATP-binding site, green: mutations in regions
that are important for actin interactions. Black lines between individual mutations indicate their combined presence in a single patient. B: The
missense mutations found in the motor domain of myosin Vb associated with non-MVID patients with intrahepatic cholestasis are depicted with
the following color code: green: mutations in regions that are important for actin interactions, red: mutations in the ATP-binding site, magenta:
mutations in regions of importance for allosteric rearrangements of the myosin head during the motor cycle, orange: mutations that may lead to
protein misfolding)
3.1 MYO5Bmutations that are not associatedwith
MVID
Some but not all MVID patients have been reported to develop
intrahepatic cholestasis that results in high levels of plasma bile acids.
It was suggested that the MYO5B mutations and consequential loss
of myosin Vb protein function may lead to defective trafficking of
the bile acid transporter ABCB11/BSEP to the apical bile canalicular
surface of hepatocytes in the liver, thereby blocking the enterohepatic
circulation of bile acids and leading to elevated plasma bile acid levels
(Girard et al., 2014; Halac et al., 2011). Recently, 26MYO5Bmutations
were reported in 17 patients with intrahepatic cholestasis but without
symptoms of MVID (Gonzales et al., 2017; Qiu et al., 2017) (Supp.
Table S1B). Interestingly, twoMYO5Bmissensemutations which affect
the same arginine residue at position 401 were identified in two unre-
lated patients presenting with either intrahepatic cholestasis without
MVID (c.1201C > T, p.Arg401Cys), and with MVID (c.1202G > A,
p.Arg401His), respectively (Qiu et al., 2017; Ruemmele et al., 2010;
van der Velde et al., 2013) (Supp. Table S1B). The previously described
p.Arg401His substitution likely affects the motor U50 subdomain
fold and thus the allosteric motor activity (van der Velde et al.,
2013), whereas the p.Arg401Cys substitution is compatible with
the motor structure in different states and might be less damaging
(Supp. Table S1B and Figure 3A and B). Another MYO5B nonsense
mutation (c.1021C > T (p.Gln341*)) was identified in a heterozygous
patient with isolated intrahepatic cholestasis without MVID and
also in an unrelated homozygous patient with MVID (Müller et al.,
2008; Qiu et al., 2017) (Supp. Table S1B). Additionally, the monoallelic
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c.1136G > C mutation (Qiu et al., 2017) leads to a p.Arg379Pro
substitution at the beginning of the actin-binding HCM loop in the
U50 subdomain (the name of this loop “hypertrophic cardiomyopathy
(HCM)” is linked to the deadly disease caused by the Arg403Gln sub-
stitution in beta-cardiac myosin (Nag et al., 2015)). While a proline is a
naturally occurring residue at this position for somemyosin II, whether
the p.Arg379Pro substitution can alter the performance of myosin V
and its processivity requires further investigations. Further, we found
that the heterozygous p.Gln1079His substitution in the coiled-coil
region of the myosin Vb protein, resulting from the heterozygous
c.3237G>Cmutation (Qiu et al., 2017), naturally occurs in themyosin
Vb sequence of the platypus (Ornithorhynchus anatinus), and is thus
unlikely to have much influence on motor function. Patients with
isolated cholestasis and MYO5B mutations are more often heterozy-
gous (82% (14 out of 17)) when compared to patients with MVID and
MYO5B mutations (67% heterozygosity (35 out of 52)), although this
is not statistically significant (Fisher Exact test P = 0.35). The myosin
VB homology protein structure-based analyses (summarized in Supp.
Table S1B, Figures 2A and 3) show that the compound heterozygous
patients with isolated cholestasis and MYO5B mutations often carry
in one allele a mutation that corresponds to more peripheral residues
of the motor domain that are predicted to be less damaging for motor
function. It is possible that this results in sufficient activity for at least
one of the mutated myosin Vb proteins. Qiu and colleagues noted that
biallelic severe MYO5B mutations (that is, truncations and splicing
mutations) and biallelic MYO5B mutations that were predicted to
affect the myosin Vb-rab11a interaction domains were less frequent
in patients with isolated cholestasis when compared to patients with
MVID (Figures 2B and 3A). This led to suggest that the severity of the
(combined) MYO5B mutations contributes to the clinical phenotype
(that is, isolatedMVID, MVID with cholestasis or isolated cholestasis).
However, as siblings with the same mutations were reported to show
differential age-of-onset and course of liver symptoms a modifying
role of other genes, epigenetics or environmental factors should also
be considered (Qiu et al., 2017).
How can mild MYO5B mutations lead to isolated cholestasis with-
out intestinal symptoms while severe MYO5B mutations can lead to
intestinal symptomswithout cholestasis? As a possible explanation we
propose that severe MYO5B mutations prevent the reabsorption of
bile acids from the intestine via the apical sodium-dependent bile acid
transporter ASBT/SLC10A2. Given that in a normal situation ∼95%
of the circulating bile acids are reabsorbed in the intestine and trans-
ported back to the liver via the portal vein, loss of ASBT/SLC10A2-
mediated reabsorption would drastically limit the bile acid load on the
liver and thereby the cholestasis phenotype. Importantly, such a sce-
nario implies that physiological parameters co-determine the clinical
outcome in patients with (a) givenMYO5Bmutation(s).
4 STX3 AND STXBP2 MUTATIONS
We have retrieved three unique STX3 and 51 unique STXBP
disease-relevant mutations from the scientific literature. At least
two and six of these STX3 and STXBP2 mutations, respectively, have
been reported to be associated with MVID-resembling congenital
diarrheal disorder (based on immunohistological biopsy inspection)
(Stepensky et al., 2013;Wiegerinck et al., 2014) (Supp. Tables S2A and
S3A), and nine more STXBP2 mutations have been associated with
FLH5-independent chronic diarrhea (Supp. Table S3A).
The STX3 encoded syntaxin-3 is a member of the SNARE pro-
tein family. STX3 contains a transmembrane C-terminal anchor (TMD)
and cytoplasmic SNARE motif (also referred to as H3 domain), a
three �-helix bundle (Habc domain), and a short N-terminal exten-
sion, known as N-peptide (Figure 4A). The SNARE motifs from differ-
ent SNARE proteins assemble to form a parallel four-helix bundle that
bridge membranes and mediate their fusion (Rizo & Südhof, 2012).
The STXBP2 encoded munc18-2 belongs to the sec1/munc18-like pro-
tein family. Munc18-2 is composed of three domains (Figure 4B): the
N-terminal domain 1 together with domain 2 forms one-half of the
protein arch-shaped structure, whereas the other half of the arch is
predominantly formed by domain 3 (Hackmann et al., 2013). Munc18-
2 forms a complex with syntaxin-3 and other SNARE proteins, thereby
regulating the specificity and productivity of SNARE-mediated mem-
brane fusion at the brush border membrane (Rizo & Südhof, 2012).
The munc18-2 structure is known (Hackmann et al., 2013), but
there is no structural information available for syntaxin-3. However,
the structure of a homologous syntaxin-1A and its complex with
syntaxin-binding protein 1 (STXBP1 or munc18-1) has been exten-
sively characterized (Burkhardt, Hattendorf, Weis, & Fasshauer, 2008;
Colbert et al., 2013; Lerman, Robblee, Fairman, & Hughson, 2000).
In the syntaxin-1A/munc18-1 crystal structure (Burkhardt et al.,
2008), syntaxin-1A bound to munc18-1 adopts a closed conformation
in which a regulatory Habc domain three helix bundle (Fernandez
et al., 1998), interacts with H3 (SNARE motif) domain, and masks the
SNARE motif required for SNARE complex assembly (Figure 4C). The
closed syntaxin-1A binds within the munc18-1 cleft that is formed
by two of the three domains (domain-1 and domain-3) (Figure 4D).
The N-terminal region of syntaxin-1A also interacts with domain-1
and this serves as a second binding site in the syntaxin-1A:munc18-1
complex (Burkhardt et al., 2008). Munc13-1 MUN domain binding
to the syntaxin-1A linker between Habc and H3 domains initiates
its conformational change favoring a transition from the munc18-
1/syntaxin-1 complex to the SNARE complex (Wang et al., 2017).
Syntaxin-3 shares 63% sequence identity and 80% sequence homol-
ogy with syntaxin-1A. Munc18-2 shares 62% sequence identity and
80% sequence homology with syntaxin-1A and has a similar structure
(Hackmann et al., 2013). This allowed us to model a putative syntaxin-
3:munc18-2 complex structure (Figure 4C) in order to address the
possible functional consequences of identified STX3 and STXBP2
mutations.
4.1 STX3
For STX3 mutation analyses, Genbank sequence (reference
AJ002076.1) was used. The two homozygous STX3 mutations,
which cosegregated with the disease in the families, included a non-
sense mutation c.739C > T (p.Arg247*) in exon 9 and a frame-shifting
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F IGURE 4 Overview of mutations in STX3 and STXBP2. A: The syntaxin-3 protein with known domains and locations of STX3 mutations. B:
Overview of the munc18-2 protein with known domains and locations of STXBP2 mutations associated with chronic diarrhea in patients. C: A
homology model of syntaxin-3-munc18-2 complex based on syntaxin-1/munc18-1 and munc18-2 crystal structures (PDB ID 4JEU, 4CCA). In
closed conformation of syntaxin-3 regulatory Habc domain (composed of three helixes a, b, c) interacts with H3 domain containing a SNAREmotif.
Munc18-2 domains 1 (dom 1) and 3 create a main syntaxin-3-binding surface. Syntaxin-3 N-terminal peptide binds to the opposite surface of the
domain 1. Residues affected by MVID related mutations are shown in spheres and labeled. D: Overview of the munc18-2 protein with known
domains and locations of STXBP2mutations associatedwith absence of chronic diarrhea in patients.Mutations indicted in black, red, gray, and blue
represent missense, frameshift/nonsense, splicing, and deletions, respectively
insertion c.372_373dup (p.Arg125Leufs*7) in exon 6 (Wiegerinck
et al., 2014) (Supp. Table S2A). The c.372_373dup (p.Arg125Leufs*7)
mutation causes the introduction of a stop codon in the N-terminal
syntaxin domain (HC) (Figure 4A) and resulted in the loss of syntaxin-3
protein expression, as evidenced byWestern blot analysis (Wiegerinck
et al., 2014). The c.739C > T (p.Arg247*) STX3 mutation introduces a
stop codon in the central SNARE domain (Figure 4A) and resulted in
a truncated protein lacking part of the SNARE-motif and the entire
C-terminal transmembrane domain (TMD) and extracellular part of
the protein, rendering the protein cytosolic (Wiegerinck et al., 2014).
Notably, a homozygousmissense STX3mutation was also identified
in a patient with autosomal recessive congenital cataract and intel-
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lectual disability phenotype without reported intestinal symptoms
(Chograni et al., 2015). This c.122A > G mutation is predicted to
lead to the substitution of a glutamic acid with a glycine at position
41 which is on the surface of the first helix of the Habc regulatory
domain of syntaxin-3 (Figure 4A and C). The residue is not involved
in munc18-2 binding. Substitution of the residue to a glycine intro-
duces flexibility in the protein main chain and may destabilize the
helix. The Glu41 residue contributes to a negatively charged cluster
on the surface of helix-a of syntaxin that overlaps with the apical
membrane targeting motif (aa 31–36) at the beginning of the helix-a
of syntaxin-3 (Sharma, Low, Misra, Pallavi, & Weimbs, 2006). This
suggests a potential contribution of the Glu41 residue to the correct
membrane localization of syntaxin-3 (Supp. Table S2B). While the
retina and brain (both affected in this patient) differentially express
the alternatively spliced syntaxin-3B and -3A variants, respectively
(Curtis et al., 2008), the Glu41 residue is conserved in all syntaxin-3
splice variants, which explains why both organs can be affected.
However, the absence of intestinal symptoms in this patient is not
easily explained and will require further investigations to reveal
whether the mutation indeed affects the stability of the protein and
whether in the case of intestinal cells, the syntaxin-3 function is
compensated by other proteins. The identification of disease-causing
STX3 mutations in patients with completely different clinical features
highlights the need for functional genotype–phenotype correlation
studies.
4.2 STXBP2
For STXBP2 mutation analyses, nucleotide/protein sequence from
Genbank (U63533.1) was used. In the munc18-2 protein architecture,
domain-2 supports the relative orientation of the domains -1 and -
3, forming a syntaxin-binding surface (Figure 4C). All the substituted
residues resulting from the missense mutations (Supp. Table S3A) as
well as the deletion mutations (p.Ile232del, p.Val367_Gln369del) in
STXBP2 are buried in the protein core and would destabilize the fold-
ing of this protein and therefore perturb the integrity of themunc18-2
structure and its functions (Supp. Table S3A and Figure 4C). The sub-
stitutions in domain-2 include p.Pro477Leu (found in a buried envi-
ronment within the protein core that cannot accommodate a bigger
side chain), p.Leu534Pro (a critical residue in the central strand of the
domain-2 beta sheet; its mutation to a proline would drastically desta-
bilize the fold), and p.Gly541Ser (the absence of a side-chain for this
residue is critical for the fold of subdomain-2) (Hackmann et al., 2013).
In addition, the p.Arg405Trp substitution is localized in the interface
between domain-2 and -3. The Arg405 residue maintains a salt bridge
that stabilizes the arched domain-3 conformation (Hackmann et al.,
2013). Its substitution by a bulky tryptophanwould destabilize the rel-
ative orientation of domain-2 and -3 and therefore also the binding site
for syntaxin that requires a precise relative positioning of subdomain -
1 and -3.
In FHL5 families withmore than one child affected, intestinal symp-
toms were either present or absent in all affected siblings, suggest-
ing that the presence or absence of intestinal symptoms in FHL5
patients is related to family-specific STXBP2 mutations. An important
question therefore is whether and, if so how, specific STXBP2 muta-
tions can be correlated to intestinal symptoms. Pagel and colleagues
noted that most FHL5 patients that carried the exon 15-skipping
frameshift mutation p.Val417Leufs*126 in STXBP2 (Figure 4D) on at
least one allele appeared protected from intestinal symptoms (Pagel
et al., 2012) (Supp. Table S3B, 11 out of 13 patients). Neverthe-
less, two FHL5 patients, one heterozygous and one homozygous for
this p.Val417Leufs*126 mutation, were reported positive for intesti-
nal symptoms (Figure 4B) (Supp. Table S3A). In the collected patient
data, we also identified a male FHL5 patient with a homozygous
p.Pro774Leu missense mutation in STXBP2 with reported intestinal
symptoms (Figure 4B), whereas two male siblings with the same
homozygous mutation were reported without intestinal symptoms
(Figure 4D and Supp. Table S3A and B). Further, a heterozygous
p.Gly541Ser substitution in STXBP2 resulting from a c.1621G>Amis-
sense mutation was predicted in a male FHL5 patient with intestinal
symptoms (Figure4B) and in two female FHL5patientswithout intesti-
nal symptoms (Figure 4D and Supp. Table S3A and B). Substitution of
theGly541 residuewith a glutamate inmunc18-2 inhibited its capacity
to bind syntaxin-3by∼60% (Riento et al., 2000). Thus, at least for these
three STXBP2mutations, there is as yet no clear genotype–phenotype
correlation with regard to the occurrence of intestinal symptoms in
FHL5 patients.
Taken together, we conclude that in vitro and patient tissue-based
data clearly indicate that myosin Vb, syntaxin-3, and munc18-2 are
functionally linked in the process of brush border protein trafficking
and brush border development, but that the precise disease mech-
anism associated with specific mutations in the individual proteins
requires further study. Clearly, our structure–function analyses only
provide predictions and supporting biochemical analyses are eagerly
awaited. Our analyses may help to delineate which mutations would
be most useful to study, for exampleMYO5B mutations that based on
structural prediction should strongly impair the protein's motor func-
tion but do not have much or highly variable consequences for the dis-
ease in terms of clinical symptoms.
5 AN EXPANDED MVID PATIENT
REGISTRY AND DATABASE OF
MVID-ASSOCIATED GENE MUTATIONS
We have updated the dataset containing all known MYO5B muta-
tions including information on gender, ancestry, consanguinity, the
intron/exon involved and predicted consequence for the protein. In
addition, we have expanded the registry with a dataset that includes
patients with (variant) MVID and STX3 mutations and a dataset
that includes FLH-5 patients with (variant) MVID and their STXBP2
mutations, together with clinical information with regard to their
intestinal symptoms. The registry now includes 188 patients with
(variant) MVID and 106 mutations. The inclusion of patients with
STX3 or STXBP2mutations in the registry allows the future correlation
and comparison of the clinical course of the disease and the genes
involved.
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6 ANIMAL MODELS FOR MVID:
VERTEBRATES ONLY?
Animal models have been developed which demonstrated that the
germline or conditional deletion of the Myo5b gene in mice or its
ortholog in zebrafish causes the clinical and cellular hallmarks of
MVID (Cartón-García et al., 2015; Schneeberger et al., 2015; Sidhaye
et al., 2016; Weis et al., 2016), thereby formally proving the causality
between loss of myosin Vb function and MVID (Cartón-García et al.,
2015). There are no reported mouse models in which Stxbp2 or Stx3 is
deleted.
In addition to Myo5b, mice in which Rab8a, Rab11a, or Cdc42 was
deleted in the intestine also showed typical hallmarks of MVID. No
mutations in RAB8, RAB11A, or CDC42 have thus far been reported
in MVID patients, although RAB11A single nucleotide polymorphisms
have been detected in at least twoMVID patients (Szperl et al., 2011).
Interestingly, rab8a expression was shown to be downregulated at the
protein level in intestinal mucosa of at least one MVID patient (Sato
et al., 2007), and rab11a was shown to be mislocalized in the entero-
cytes of MVID patient small intestinal biopsies (Dhekne et al., 2014;
Golachowska et al., 2012; Szperl et al., 2011). Likewise, cdc42 has been
reported to be mislocalized in the enterocytes of MVID patient small
intestine biopsies (Michaux et al., 2015). These and other data from
cell lines (Knowles et al., 2014) suggest the functional involvement of
rab8a, rab11a and cdc42withmyosin Vb in the pathogenesis ofMVID.
The animal models will be of great value for further elucidation of
the cellular and molecular mechanisms that underlie congenital diar-
rheal disorders centered around MVID, and for the preclinical testing
of therapeutic strategies. The zebrafishmodel forMVIDmay be partic-
ularly useful for high-throughput testing of potential therapeutic com-
pounds.
Notably, in contrast to vertebrate mice and zebrafish, the inverte-
brateDrosophila melanogaster (fruit fly) in which the myosin V ortholog
didum was deleted did not show an intestinal phenotype, despite the
abundant expression level of myosin V in the wild-type digestive sys-
tem and its distribution to punctate subapical vesicles (Mermall et al.,
2005), which is very similar to its distribution to human epithelial cells
(Dhekne et al., 2014; Goldenring et al., 1996). Similarly, the deletion of
the MYO5B ortholog Hum-2 in Caenorhabditis elegans (nematode) did
not show an intestinal phenotype (Winter et al., 2012). In contrast to
humans, mice, and zebrafish, which have threeMYO5 family members
(A–C), the invertebrate D. melanogaster and C. elegans have only a sin-
gleMYO5 gene. Thus, it appears that the critical role of myosin V in the
differentiation and function of enterocytes is restricted to vertebrates
and evolved with the appearance of multiple myosin V isoforms. There
are no reports with regard to the function of syntaxin-3 or munc18-2
in the invertebrate digestive system.
7 FUTURE PERSPECTIVES
Clearly, MVID presents as a heterogeneous disease with an expand-
ing spectrum of genotypes and phenotypes. Diagnosis of MVID must
include, besides the clinical symptoms, immunohistochemistry analy-
ses ofCD10andPAS staining ad electronmicroscopy in duodenal biop-
sies followed by mutation analyses of the MYO5B, STX3, and STXBP2
genes.
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